Thursday, October 22, 2026
25.6 C
Bengaluru

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry Needed

For decades, Indian pharma has won by playing the volume game—generics, cost arbitrage, regulatory stamina, scale. That model built giants. It also hit a ceiling.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

Anuj Pasrija has been elevated to Country Lead, Johnson...

China’s Biopharma Strategy: A Warning and Opportunity for India

China is playing a long game in biopharma. And...

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

With over two decades of experience across finance, strategy,...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Topics

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of...
spot_img

Related Articles

spot_imgspot_img